Literature DB >> 30980317

Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.

Tomoyuki Sugimoto1, Toshimitsu Hamasaki2, Scott R Evans3, Susan Halabi4.   

Abstract

We discuss the multivariate (2L-variate) correlation structure and the asymptotic distribution for the group-sequential weighted logrank statistics formulated when monitoring two correlated event-time outcomes in clinical trials. The asymptotic distribution and the variance-covariance for the 2L-variate weighted logrank statistic are derived as available in various group-sequential trial designs. These methods are used to determine a group-sequential testing procedure based on calendar times or information fractions. We apply the theoretical results to a group-sequential method for monitoring a clinical trial with early stopping for efficacy when the trial is designed to evaluate the joint effect on two correlated event-time outcomes. We illustrate the method with application to a clinical trial and describe how to calculate the required sample sizes and numbers of events.

Entities:  

Keywords:  Bivariate dependence; Error-spending method; Independent censoring; Logrank statistic; Non-fatal events; Normal approximation

Mesh:

Year:  2019        PMID: 30980317      PMCID: PMC7517875          DOI: 10.1007/s10985-019-09470-4

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  21 in total

1.  Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.

Authors:  Ajit C Tamhane; Yi Wu; Cyrus R Mehta
Journal:  Stat Med       Date:  2012-06-22       Impact factor: 2.373

2.  Simultaneous group sequential analysis of rank-based and weighted Kaplan-Meier tests for paired censored survival data.

Authors:  Adin-Cristian Andrei; Susan Murray
Journal:  Biometrics       Date:  2005-09       Impact factor: 2.571

3.  Sample size calculation for the weighted rank statistics with paired survival data.

Authors:  Sin-Ho Jung
Journal:  Stat Med       Date:  2008-07-30       Impact factor: 2.373

4.  Hierarchical testing of multiple endpoints in group-sequential trials.

Authors:  Ekkehard Glimm; Willi Maurer; Frank Bretz
Journal:  Stat Med       Date:  2010-01-30       Impact factor: 2.373

5.  A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.

Authors:  Tomoyuki Sugimoto; Takashi Sozu; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biostatistics       Date:  2013-01-10       Impact factor: 5.899

6.  Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Tomoyuki Sugimoto; Kenichi Hayashi; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2014-03-27       Impact factor: 2.373

7.  Guidelines for monitoring efficacy and toxicity responses in clinical trials.

Authors:  R J Cook; V T Farewell
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

8.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

9.  Sizing clinical trials when comparing bivariate time-to-event outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2017-01-24       Impact factor: 2.373

10.  Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Stat Biopharm Res       Date:  2017-03-02       Impact factor: 1.452

View more
  2 in total

1.  Interim Monitoring for Futility in Clinical Trials with Two Co-primary Endpoints Using Prediction.

Authors:  Koko Asakura; Scott R Evans; Toshimitsu Hamasaki
Journal:  Stat Biopharm Res       Date:  2019-11-04       Impact factor: 1.452

2.  On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes.

Authors:  Toshimitsu Hamasaki; H M James Hung; Chin-Fu Hsiao; Scott R Evans
Journal:  Contemp Clin Trials       Date:  2020-12-09       Impact factor: 2.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.